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plantation (HSCT) is an increasingly common treatment for
malignant and non-malignant hematologic diseases. The
major limitation to the realization of this type of transplant is
access to an HLA-identical donor within the family. Only 30%
of patients referred for transplantation will have an appro-
priate RD; using HLA-identical URD is an alternative for these
patients. The aim of this study is to describe the ﬁrst expe-
rience in Colombia with this type of transplant.
Materials and Methods: Observational case series.
Results: From July 1, 2011, have been 89 searches have been
started. The most frequent diagnosis acute leukemia (47 ALL,
25 AML). Since there isn’t a national donors registry, searches
were performed through NMDP. 26 matched-URD (10/10 or
9/10) were found (29.81%) and 14 transplants have been
performed. 8 patients with an URD died before trans-
plantation, 2 lost indication and 2 transplants are waiting.
The median time from the start of the search to ﬁnding
the donor was 52 days (range 28-240) and once the donor
was located it took a median of 67 days (range 36-94) to the
infusion.
Transplanted patients were 7 males/7 females, mean age
30 years (2-59), 9 had AML, 3 ALL and 2 SAA. Most leukemias
were in ﬁrst CR (10). Donors were on the majority young
(median 37 years; range 21-55), males (8), CMV positive.
PBSC were use in 10 cases.
Busulfan-Fludarabine-ATG conditioning regimen was
used for leukemia. GVHD prophylaxis consisted of Cs-MTX.
Survival: With a median follow up of 5.83 months (range:
0.86-17.9), 12 of the 14 patients are alive and in remission of
their disease (OS 85.7%). One patient died from aGVHD
complications and the other due to idiopathic pneumonitis. 2
of the 14 had grade III -IV aGVHD .
Conclusions: Allogeneic DNF is possible in Colombia and
results are the same that would be expected for a similar
population with RD. Low rates of success in ﬁnding an URD
for our Hispanic patients reﬂects the fact that they represent
a minority in world registries and highlight the need for the
creation of local registries.323
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Allo-SCT from an HLA related or unrelated donor is the ﬁrst
line treatment for newly diagnosed patients with BMFS
younger than 40 years, and for older patients that failed
immunosuppressive therapy.
Cohort retrospective analysis of BMFS patients receiving
Allo-SCT in a mixed (pediatric-adult) transplant center in
Bogota, Colombia, was performed to assess the inﬂuence of
different conditioning regimens in outcomes. Log-rank tests
(Lrt) analyses were used to determine the effects of age,
conditioning regimen and year of treatment on survival.Between January 1995 and August 2013, 96 transplants were
performed in 89 patients (70 acquired SAA, 16 Fanconi
Anemia, 2 pure red cell aplasia, 1 dyskeratosis congenita). 54
were males, mean age 25.8 years (range 4-60), mean time
from diagnosis to transplant 26.2 months (range 2.1-143),
60% were heavily transfused. Most donors were HLA iden-
tical siblings (81 PBSC, 7 BM); 3 transplants from unrelated
CBU, 2 from an haploidentical relative and 2 from an HLA
identical URD. Conditioning regimens used were: RIC Cy-Flu-
ATG (41), Cy-ATG (35) and Cy (14). 6 patients were condi-
tioned with Campath containing regimens and 2 with other.
Before 2004 most patients received Cs and MTX as GVHD
prophylaxis, after 2004 Cs and MMF was used in the
majority.
2 patients died due to sepsis before engraftment could be
evaluated. From the 87 evaluable patients, 5 had primary
graft failure and 4 secondary graft failure. 7/9 patients with
graft failure had a second transplant (5 from the same donor
and 2 from an haploidentical relative). 6 of those 7 trans-
plants engrafted and are alive. Non-myeloablative condi-
tioning containing Fludarabine, resulted in less hospital stay
compared to Cy-ATG and Cy alone (22.9, 32, 33 days
respectively), less fever (1.7, 6.7, 7 days), less parenteral
nutrition (0.1, 9, 4 days) and less red cells (2.4, 3.8, 3.8) and
platelet (4.5, 7.5, 9.75) transfusions. Rates of GII-IV aGVHD
were also less frequent for Cy-Flu-ATG group 8% compared to
Gy-ATG (18%) or Cy (25%). Extensive cGVHD was reported in
11%, 6% and 25% respectively.
The median follow-up was 23.06 months (range: 7.06-62.6).
Five-year overall survival (OS) was 69.23% for the entire
group. RIC-Flu-Cy-ATG resulted in signiﬁcantly better overall
survival (85.7%) compared to other regimens (66.6% for Cy-
ATG and 28.5% Cy (p¼0.0016). There was no signiﬁcant dif-
ference in survival related to age (p¼0.96). There as superior
survival for transplants performed after 2004 (n¼64)
compared with those before that year (n¼25) (80.3 vs 43.3%,
p¼0.004).
This single center experience suggest signiﬁcant overall
survival advantage of RIC-Flu-Cy-ATG over other condition-
ing regimens in high-risk BMFS patients regardless the age.
These results should be validated in prospective randomized
studies.324
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Acute and chronic GvHD occurs in 50-70% of patients un-
dergoing HCT despite GvHD prophylaxis. In this study, ECP
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S213was added as GvHD prophylaxis for 10 treatments, 2 treat-
ments prior to the start of the conditioning regimen and 8
after engraftment at two treatments every twoweeks. All pts
also received tacrolimus and methotrexate and 8 also
received ATG. 20 pts (13 males, ages 28 e 57) were enrolled.
All pts underwent a MA HCT (15 Bu-Cy and 5 Cy-TBI), 11 from
matched unrelated, 5 from related and 4 from mismatched
unrelated donors.15 had AML orMDS and 5 ALL or NHL. 4 pts
died before day 100 (RSV n¼1, GvHD and sepsis n¼1 and
relapse n¼2). 12 pts received all the 10 planned ECP treat-
ments while 8 received 2-6 of the treatments due to death
before day 100 (n¼4), relapse (n¼2), and withdrawal due to
iv access issues (n¼2). 4 patients required blood products
before ECP. AGvHD grade 2 e 4 occurred in 12 of 19 (63%)
evaluable pts while grade 3-4 occurred in 4 (21%). 4 of 14
surviving pts developed chronic GvHD (28%), 3 extensive and
1 limited. Two pts died from cGvHD. 14 patients (70%) are
alive from 5 months to 30 months post HPCT. PBMCs were
collected before ECP therapy and three months post-HPCT.
T cells were analyzed for CD45RO, B cells for IgD, and CD4+
T cells for FoxP3. In patients who developed GvHD, fewer
T cells expressed CD45RO, but more B cells had isotype class-
switched. Patients who did not develop GvHD hadmore Treg
cells (ﬁg). These data indicate ECP may be effective as pro-
phylactic therapy for cGvHD and should be further investi-
gated. The pre-transplant lymphocyte phenotype might
predict post-transplant lymphocyte activity and the efﬁcacy
of ECP as a prophylactic therapy.Figure 1. Progression-free survival for patients with advanced CML treated
with a haploidentical transplant at MD Anderson Cancer Center.325
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Background: Allogeneic stem transplantion in Chronic
Myeloid Leukemia (CML) is reserved for patients who have
accelerated phase (AP), are in blast crisis (BP), chronic phase
CML patients that have failed second-generation tyrosine
kinase inhibitors (TKIs), and those who have developed
resistant mutations to TKI such as T315I. Haploidenticalhematopoietic Stem Cell transplantation (HaploSCT) is an
alternative treatment option for patients without a matched
donor. Post-transplant cyclophosphamide (PTCy), in addition
to tacrolimus and mycophenolate, has been effective in
preventing GVHD and was associated with lower treatment-
related mortality in this type of transplant. However,
outcomes for patients with CML using this approach are
unknown, we therefore report on our experience using
haploidentical transplantation for a cohort of advanced CML
patients treated at our institution.
Patients and Methods: We performed a retrospective chart
review of patients with advanced CML who received a hap-
loidentical stem cell transplant at the MD Anderson Cancer
Center after January 2009. The objectives of this analysis
were to determine rates of engraftment, incidence of GVHD,
treatment-related mortality, relapse rates and survival. The
conditioning regimen consisted of melphalan 140mg/m2
(1 patient had 100mg/m2), thiotepa 5-10 mg/kg and ﬂudar-
abine 160mg/m2 total dose. GVHD prophylaxis consisted of
post-transplant cyclophosphamide followed by tacrolimus
andMMF as previously reported. All but one patient received
bone marrow as stem cell source.
Results: Ten patients with advanced CML were treated dur-
ing this time period. The median number of prior medical
therapies including TKIs was 3. All patients engrafted neu-
trophils after a median of 18 days, with 100% donor cells on
chimerism, and achieved remission post-transplant. Acute
grade 2-4 GVHD occurred in 30% (no grade 3 -4), and overall
